clinical trial · NCT07483073
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Eli Lilly and Company·phase2·recruiting·n = 60
Colitis, UlcerativeCrohn DiseaseMirikizumab - Intravenous (IV)Mirikizumab - Subcutaneous (SC)LY4395089
brief summary
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.
started
May 4, 2026
primary completion
Jun 1, 2027
completion
Mar 1, 2028
last updated
May 19, 2026
official title
A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol